Italia markets open in 1 hour 46 minutes

Sysmex Corporation (6869.T)

Tokyo - Tokyo Prezzo differito. Valuta in JPY.
Aggiungi a watchlist
8.903,00+207,00 (+2,38%)
Alla chiusura: 02:54PM JST

Sysmex Corporation

1-5-1 Wakinohama-kaigandori
Chuo-ku
Kobe 651-0073
Japan
81 78 265 0500
https://www.sysmex.co.jp

Settore/iHealthcare
SettoreMedical Instruments & Supplies
Impiegati a tempo pieno8.771

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Hisashi IetsuguChairman of the Managing Board & CEO210MN/D1949
Mr. Kaoru AsanoCTO, Sr. MD, Sr. Exec. Officer, Sr. MD & Member of the Managing BoardN/DN/D1958
Mr. Iwane MatsuiMD of Global Marketing, Sr. Exec. Officer & Member of Managing BoardN/DN/D1961
Mr. Kenji TachibanaSr. MD of Corp Mgmt & Regulatory Affairs, Sr. Exec. Officer & Member of the Managing BoardN/DN/D1957
Mr. Hiroshi KandaMD of Bus. Strategy Devel., Sr. Exec. Officer & Member of the Managing BoardN/DN/D1957
Mr. Mamoru KubotaSr. Exec. Officer & Deputy in charge of Bus. Strategy Devel.N/DN/DN/D
Mr. Kensuke LizukaSr. Exec. Officer & Exec. VP of Corp. Bus. Planning Div.N/DN/DN/D
Mr. Tomokazu YoshidaSr. Exec. Officer, MD of R&D, Incubation & MR Bus. and Member of the Managing BoardN/DN/D1964
Mr. Takashi OnoSr. Exec. OfficerN/DN/DN/D
Mr. Mitsuhisa KanagawaExec. Officer of IVD Bus. Unit & Exec. VP of Bus. Strategy Devel.N/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in JPY.

Descrizione

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Governance aziendale

L'ISS Governance QualityScore di Sysmex Corporation al 1 dicembre 2022 è 4. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 3; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.